Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis

AIDS

Volumn 28, Issue 11, 2014, Pages 1673-1678

  Kuhn, Louise ^a   Hunt, Gillian ^b   Technau, Karl Günter ^c   Coovadia, Ashraf ^c   Ledwaba, Johanna ^b   Pickerill, Sam ^c   Penazzato, Martina ^d   Bertagnolio, Silvia ^e   Mellins, Claude A ^f   Black, Vivian ^g   Morris, Lynn ^b   Abrams, Elaine J ^h  

^a Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^b National Health Laboratory Service   (United States)

^c Faculty of Health Sciences Empilweni Services and Research Unit Department of Paediatrics and Child Health   (South Africa)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f HIV Center for Clinical and Behavioral Studies   (United States)

^g UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^h ICAP Mailman School of Public Health Department of Pediatrics ^*  (United States)

Author keywords

Children; Drug resistance; Nonnucleoside reverse transcriptase inhibitor resistance; Prevention of mother to child transmission

Indexed keywords

EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS NEVIRAPINE PLUS TENOFOVIR DISOPROXIL; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA;

ANTIVIRAL RESISTANCE; ARTICLE; CHILD; DRUG EFFICACY; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; PREGNANT WOMAN; PREVALENCE; PRIORITY JOURNAL; SOUTH AFRICA; TREATMENT INDICATION; VIRUS MUTATION; CHEMOPROPHYLAXIS; DRUG EFFECTS; EPIDEMIOLOGY; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; INFANT; ISOLATION AND PURIFICATION; MUTATION; NEWBORN; PLASMA; PREGNANCY; PROCEDURES; VIROLOGY;

ANTI-HIV AGENTS; CHEMOPREVENTION; DRUG RESISTANCE, VIRAL; FEMALE; HIV; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MUTATION; PLASMA; PREGNANCY; PREVALENCE; RNA, VIRAL; SOUTH AFRICA;

EID: 84904733167     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000261     Document Type: Article

References (19)

1. Paredes R, Marconi VC, Lockman S, Abrams EJ, Kuhn L. Impact of antiretroviral drugs in pregnant women and their children in Africa: HIV resistance and treatment outcomes. J Infect Dis 2013; 207 (Suppl 2): S93-S100.
2. Ton Q, Frenkel L. HIV drug resistance in mothers and infants following use of antiretrovirals to prevent mother-To-child transmission. Curr HIV Res 2013; 11: 126-136.
3. Penazzato M. WHO HIV drug resistance surveillance in children less than 18 months old newly diagnosed with HIV: results from Swaziland and Zimbabwe. 5th International Workshop on HIV Pediatrics, Kuala Lumpur, Malaysia: 28-29 June 2013 (Abstract O-2012AB).
4. Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, Moffat C, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 2010; 362: 2282-2294.
5. National Department of Health. Policy and Guidelines for the Implementation of the PMTCT Program. 2008 ed. Pretoria: National Department of Health; 2008.
6. National Department of Health. Clinical Guidelines: PMTCT (Prevention of Mother-To-Child Transmission). 2010 ed. Pretoria: National Department of Health; 2010.
7. Pillay V, Ledwaba J, Hunt G, Rakgotho M, Singh B, Makubalo L, et al. Antiretroviral drug resistance surveillance among drugnaive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther 2008; 13 (Suppl 2): 101-107.
8. Zhou Z, Wagar N, DeVos JR, Rottinghaus E, Diallo K, Nguyen DB, et al. Optimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settings. PLoS One 2011; 6: e28184.
9. Loubser S, Balfe P, Sherman G, Hammer S, Kuhn L, Morris L. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-To-child HIV transmission. AIDS 2006; 20: 995-1002.
10. Hunt GM, Coovadia A, Abrams EJ, Sherman G, Meyers T, Morris L, et al. HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine. AIDS 2011; 25: 1461-1469.
11. Martinson NA, Morris L, Gray G, Moodley D, Pillay V, Cohen S, et al. Selection and persistence of viral resistance in HIVinfected children after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr 2007; 44: 148-153.
12. Kuhn L, Coovadia A, Strehlau R, Martens L, Hu CC, Meyers T, et al. Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-Term follow-up of a randomised, open-label trial. Lancet Infect Dis 2012; 12: 521-530.
13. Martinson NA, Morris L, Johnson J, Gray GE, Pillay V, Ledwaba J, et al. Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance. AIDS 2009; 23: 809-816.
14. Hunt GM, Ledwaba J, Basson AE, Moyes J, Cohen C, Singh B, et al. Surveillance of transmitted HIV-1 drug resistance in Gauteng and KwaZulu-Natal Provinces, South Africa, 2005-2009. Clin Infect Dis 2012; 54 (Suppl 4): S334-S338.
15. Kahle EM, Kashuba A, Baeten JM, Fife KH, Celem C, Mujugira A, et al. Unreported antiretroviral use by HIV-1 infected participants enrolling in a prospective research study. J Acquir Immune Defic Syndr (JAIDS) 2014; 65: e90-e94.
16. Bertagnolio S, Penazzato M, Jordan MR, Persaud D, Mofenson LM, Bennett DE. World Health Organization generic protocol to assess drug-resistant HIV among children <18 months of age and newly diagnosed with HIV in resource-limited countries. Clin Infect Dis 2012; 54 (Suppl 4): S254-S260.
17. Goga AE, Dinh TH, Jackson DJ, for the SAPMTCTE study group. Impact of the national prevention of mother-To-child transmission of HIV (PMTCT) program on perinatal mother-To-child transmission of HIV (MTCT) measured at six weeks postpartum, South Africa (SA). In: XIX International AIDS Conference. Washington; 2012.
18. Palumbo P, Lindsey JC, Hughes MD, Cotton MF, Bobat R, Meyers T, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med 2010; 363: 1510-1520.
19. Violari A, Lindsey JC, Hughes MD, Mujuru HA, Barlow-Mosha L, Kamthunzi P, et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med 2012; 366: 2380-2389.